SomaGenics Inc. (SomaGenics) is engaged in developing novel RNA-based translation inhibitors for functional genomics. Its therapeutic programs use proprietary RNA interference methods to diagnose hepatitis C, HIV and psoriasis. SomaGenics has 11 issued or pending patents across all major markets in various areas such as direct-delivered shRNA therapeutics, directed libraries and nucleic acid detection. The company has collaborations with various institutions, which includes University of Texas/MD Anderson Cancer Center, Stanford, Texas A&M, Princeton, City of Hope National Medical Center, Indiana University, Harvard Medical School, Georgetown University, UC San Francisco, UC Los Angeles and UC Santa Cruz. The company is headquartered in California, the US.